Nutex Health Inc. (NUTX)
NASDAQ: NUTX
· Real-Time Price · USD
83.44
0.06 (0.07%)
At close: Sep 08, 2025, 10:46 AM
Nutex Health Revenue Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Division Revenue | 203.95M | 377.33M | 71.73M | 67.6M | 60.03M | 62.59M | 54.59M | 51.61M | 49.29M | 177.26M | 21.24M |
| Hospital Division Revenue Growth | -45.95% | +426.03% | +6.11% | +12.62% | -4.08% | +14.66% | +5.76% | +4.71% | -72.20% | +734.41% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 10.04M | 27.43M | 11.83M | 10.59M | 8.71M | 9.14M | 7.84M | 10.01M | 9.08M | 6.31M | 4.08M | 2.49M | 17.79M | -103.33M | 1.55M | 1.53M | 4.44M | 41.09M | 693.35K | 1.39M | 957.23K | 3.67M | 187.29K | 198.95K | 190.26K | 410.84K | 207.79K | 310.87K | 234.26K | 606.65K | 723K | 1.24M |
| Selling, General, and Administrative Revenue Growth | -63.41% | +131.88% | +11.69% | +21.63% | -4.70% | +16.48% | -21.63% | +10.29% | +43.85% | +54.74% | +64.05% | -86.03% | -117.22% | -6785.30% | +0.83% | -65.44% | -89.20% | +5826.20% | -50.28% | +45.67% | -73.91% | +1858.62% | -5.86% | +4.57% | -53.69% | +97.71% | -33.16% | +32.70% | -61.38% | -16.09% | -41.63% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -73.75K | n/a | n/a | 73.75K | 209.16K | 72.27K | 59.63K | 76.72K | 54.3K | 73.83K | 314.25K | 114.88K | 768.1K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | -100.00% | -64.74% | +189.43% | +21.19% | -22.28% | +41.30% | -26.46% | -76.51% | +173.55% | -85.04% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |